Search

Your search keyword '"Pillai, Satish"' showing total 712 results

Search Constraints

Start Over You searched for: Author "Pillai, Satish" Remove constraint Author: "Pillai, Satish"
712 results on '"Pillai, Satish"'

Search Results

1. A pan-respiratory antiviral chemotype targeting a transient host multi-protein complex.

2. Systematic benchmarking of single-cell ATAC-sequencing protocols.

3. A viral assembly inhibitor blocks SARS-CoV-2 replication in airway epithelial cells.

4. The hypoxia-regulated ectonucleotidase CD73 is a host determinant of HIV latency

5. Human galectin-9 potently enhances SARS-CoV-2 replication and inflammation in airway epithelial cells

6. Host variation in type I interferon signaling genes (MX1), C-C chemokine receptor type 5 gene, and major histocompatibility complex class I alleles in treated HIV+ noncontrollers predict viral reservoir size.

7. Galectin-9 protects humanized-ACE2 immunocompetent mice from SARS-CoV-2 infection.

9. Hyaluronic acid is a negative regulator of mucosal fibroblast-mediated enhancement of HIV infection

10. Efficient generation of isogenic primary human myeloid cells using CRISPR-Cas9 ribonucleoproteins

11. Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo

12. TCF-1 regulates HIV-specific CD8+ T cell expansion capacity

13. μ‐Lat: A mouse model to evaluate human immunodeficiency virus eradication strategies

14. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.

15. FOXO1 promotes HIV latency by suppressing ER stress in T cells

16. Seminal Plasma-Derived Extracellular-Vesicle Fractions from HIV-Infected Men Exhibit Unique MicroRNA Signatures and Induce a Proinflammatory Response in Cells Isolated from the Female Reproductive Tract

17. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area.

18. Enhanced Adenovirus Vaccine Safety Surveillance in Military Setting, United States

19. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals

21. Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency.

22. Distinct chromatin functional states correlate with HIV latency reactivation in infected primary CD4+ T cells.

23. Granulocyte-Derived Extracellular Vesicles Activate Monocytes and Are Associated With Mortality in Intensive Care Unit Patients

24. Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.

25. HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication

26. Signature of the Sleeper Cell: A Biomarker of HIV Latency Revealed

27. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

28. Identification and characterization of a rich population of CD34+ mesenchymal stem/stromal cells in human parotid, sublingual and submandibular glands.

29. Cytokines Elevated in HIV Elite Controllers Reduce HIV Replication In Vitro and Modulate HIV Restriction Factor Expression

30. Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies

31. Population Movement Patterns Among the Democratic Republic of the Congo, Rwanda, and Uganda During an Outbreak of Ebola Virus Disease : Results from Community Engagement in Two Districts — Uganda, March 2019

32. Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation.

33. Investigation and Serologic Follow-Up of Contacts of Early Confirmed Case-Patient with COVID-19, Washington, USA

34. Modulation of Cellular Protein Trafficking by Human Immunodeficiency Virus Type 1 Nef: Role of the Acidic Residue in the ExxxLL Motif

35. Select host restriction factors are associated with HIV persistence during antiretroviral therapy

36. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

37. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

39. Decreased HIV Type 1 Transcription in CCR5-Δ32 Heterozygotes During Suppressive Antiretroviral Therapy

40. Dynamic Regulation of Host Restriction Factor Expression over the Course of HIV-1 Infection In Vivo

42. Initial Public Health Laboratory Response After Hurricane Maria — Puerto Rico, 2017

43. Effects of Alpha Interferon Treatment on Intrinsic Anti-HIV-1 Immunity In Vivo

44. Expression profile of host restriction factors in HIV-1 elite controllers

45. Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient

46. Human Endogenous Retrovirus K106 (HERV-K106) Was Infectious after the Emergence of Anatomically Modern Humans

48. In vivo CD8+ T-cell suppression of siv viremia is not mediated by CTL clearance of productively infected cells.

49. Systematic benchmarking of single-cell ATAC-sequencing protocols

50. A Novel Viral Assembly Inhibitor Blocks SARS-CoV-2 Replication in Airway Epithelial Cells

Catalog

Books, media, physical & digital resources